Compare DexCom, Inc. (DXCM) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Li Auto Inc — how do they compare? DexCom, Inc. trades at $77.84 (market cap $28.06B), while Li Auto Inc trades at $13 (market cap $12.31B). The key difference: DexCom, Inc. is far larger — about 2.3× Li Auto Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | LI | |
|---|---|---|
Market Cap | $28.06B | $12.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $31.80 |
52-Week Low | $54.84 | $11.74 |
Enterprise Value | $27.03B | $1.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Li Auto (LI) trades at $12.47, up 2.38% today, amid mixed technical signals with a bearish overall trend. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle deliveries of 30,895 in June 2026 show ongoing operational activity despite competitive pressures in the EV market.
The outlook remains challenging with negative profit margins and high P/E ratio of 99.38, though analyst consensus targets $14.80. Key risks include intense competition and volatile earnings, while potential recovery hinges on successful execution of new models like the Li L8 launched in June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
